ClearPoint Neuro Statistics
Share Statistics
ClearPoint Neuro has 27.58M shares outstanding. The number of shares has increased by 2.26% in one year.
| Shares Outstanding | 27.58M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -0.04% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 23.89M |
| Failed to Deliver (FTD) Shares | 200 |
| FTD / Avg. Volume | 0.08% |
Short Selling Information
The latest short interest is 744.19K, so 2.7% of the outstanding shares have been sold short.
| Short Interest | 744.19K |
| Short % of Shares Out | 2.7% |
| Short % of Float | 3.11% |
| Short Ratio (days to cover) | 3.01 |
Valuation Ratios
The PE ratio is -7.56 and the forward PE ratio is -18.23.
| PE Ratio | -7.56 |
| Forward PE | -18.23 |
| PS Ratio | 6.97 |
| Forward PS | 6.3 |
| PB Ratio | 7.89 |
| P/FCF Ratio | -11.31 |
| PEG Ratio | n/a |
Enterprise Valuation
ClearPoint Neuro Inc. has an Enterprise Value (EV) of 157.87M.
| EV / Earnings | -7.15 |
| EV / Sales | 6.59 |
| EV / EBITDA | -7.52 |
| EV / EBIT | -7.03 |
| EV / FCF | -10.69 |
Financial Position
The company has a current ratio of 4.87, with a Debt / Equity ratio of 0.47.
| Current Ratio | 4.87 |
| Quick Ratio | 3.8 |
| Debt / Equity | 0.47 |
| Total Debt / Capitalization | 31.97 |
| Cash Flow / Debt | -1.38 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -1.04% and return on capital (ROIC) is -63.92%.
| Return on Equity (ROE) | -1.04% |
| Return on Assets (ROA) | -0.52% |
| Return on Capital (ROIC) | -63.92% |
| Revenue Per Employee | 223.88K |
| Profits Per Employee | -206.44K |
| Employee Count | 107 |
| Asset Turnover | 0.56 |
| Inventory Turnover | 1.31 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 94.17% in the last 52 weeks. The beta is 1.11, so ClearPoint Neuro 's price volatility has been higher than the market average.
| Beta | 1.11 |
| 52-Week Price Change | 94.17% |
| 50-Day Moving Average | 13.7 |
| 200-Day Moving Average | 9.68 |
| Relative Strength Index (RSI) | 48.77 |
| Average Volume (20 Days) | 240.45K |
Income Statement
In the last 12 months, ClearPoint Neuro had revenue of 23.95M and earned -22.09M in profits. Earnings per share was -0.9.
| Revenue | 23.95M |
| Gross Profit | 13.61M |
| Operating Income | -22.45M |
| Net Income | -22.09M |
| EBITDA | -20.99M |
| EBIT | -22.45M |
| Earnings Per Share (EPS) | -0.9 |
Balance Sheet
The company has 23.14M in cash and 13.94M in debt, giving a net cash position of 9.20M.
| Cash & Cash Equivalents | 23.14M |
| Total Debt | 13.94M |
| Net Cash | 9.20M |
| Retained Earnings | -172.46M |
| Total Assets | 40.19M |
| Working Capital | 26.78M |
Cash Flow
In the last 12 months, operating cash flow was -13.72M and capital expenditures -1.05M, giving a free cash flow of -14.77M.
| Operating Cash Flow | -13.72M |
| Capital Expenditures | -1.05M |
| Free Cash Flow | -14.77M |
| FCF Per Share | -0.6 |
Margins
Gross margin is 56.83%, with operating and profit margins of -93.7% and -92.21%.
| Gross Margin | 56.83% |
| Operating Margin | -93.7% |
| Pretax Margin | -92.21% |
| Profit Margin | -92.21% |
| EBITDA Margin | -87.62% |
| EBIT Margin | -93.7% |
| FCF Margin | -61.66% |
Dividends & Yields
CLPT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -6.14% |
| FCF Yield | -3.65% |
Analyst Forecast
The average price target for CLPT is $12, which is -18.1% lower than the current price. The consensus rating is "Strong Buy".
| Price Target | $12 |
| Price Target Difference | -18.1% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
Stock Splits
The last stock split was on Jul 27, 2016. It was a backward split with a ratio of 1:40.
| Last Split Date | Jul 27, 2016 |
| Split Type | backward |
| Split Ratio | 1:40 |
Scores
| Altman Z-Score | 17.24 |
| Piotroski F-Score | 4 |